Clinical Trials Logo

Filter by:
NCT ID: NCT04298736 Recruiting - Clinical trials for NASH - Nonalcoholic Steatohepatitis

Bariatric Surgery vs. Lifestyle Modification for NASH

BeLEANeR
Start date: February 19, 2020
Phase: N/A
Study type: Interventional

Randomized Controlled Trial comparing the effects of Bariatric Surgery vs. Lifestyle modification on NASH resolution.

NCT ID: NCT04296682 Recruiting - Clinical trials for Alveolar Ridge Preservation

Impact Of Soft Tissue Manipulation On Dimensional Changes After Posterior Region Extraction.

Start date: January 20, 2020
Phase: N/A
Study type: Interventional

Alveolar preservation seek to avoid multiple surgical interventions to the patient and decrease costs to the patient. In particular, in a Brazilian population where the need for extraction is great, the development of techniques that safely allow a higher quality of rehabilitation is of paramount importance. Thus, this analysis is of great scientific and therapeutic importance. Within the above, the objective is to use an autogenous connective tissue graft in order to eliminate the need to raise the full-thickness flap and compensate for soft tissue deficiencies, which may reduce dimensional losses after extraction, in addition to reducing the cost of the technique.

NCT ID: NCT04294927 Recruiting - Ovarian Cancer Clinical Trials

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

TUBA-WISP-II
Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

NCT ID: NCT04291105 Recruiting - Melanoma Clinical Trials

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Start date: April 24, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.

NCT ID: NCT04280029 Recruiting - Coronary Restenosis Clinical Trials

SELUTION SLR™ 014 In-stent Restenosis

SELUTION4ISR
Start date: July 6, 2020
Phase: N/A
Study type: Interventional

Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or DES and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR™ 014 DEB or SOC to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or BA. A maximum of 20% of patients randomized to SOC will be treated with BA. The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR™ 014 DEB in all patients.

NCT ID: NCT04277364 Recruiting - Muscle Strength Clinical Trials

Effects of Phosphatidic Acid on Strength and Hypertrophy

Start date: August 17, 2020
Phase: N/A
Study type: Interventional

There are indications that phosphatidic acid (PA) supplementation is capable of enhancing gains in strength and muscle mass in response to strength training, although the literature is still incipient and controversial. Given the possible benefits in terms of maintenance and increased skeletal muscle mass, which still need confirmation, this study aims to examine the effectiveness of PA supplementation in two different doses in increasing skeletal muscle mass and strength in adult men undergoing to 8 weeks of strength training. For this, about 45 men will be randomly allocated to one of three treatments at a ratio of 1:1:1: PA 750mg per day, PA 375mg per day, or placebo (cornstarch, 750mg per day). All participants will undergo a 8-week strength training program, 3 times a week, totaling 24 sessions, which will begin with the start of supplementation. Individuals will be assessed for maximum dynamic strength of upper and lower limbs, resistance to dynamic strength of upper and lower limbs, body composition, muscle cross-sectional area and food consumption. Samples of venous blood will also be collected to determine the concentration of creatine kinase (CK), lactate dehydrogenase (LDH), testosterone, insulin-like growth factor type 1 (IGF-1), growth hormone (GH) and cortisol. These evaluations will be carried out before (PRE) and after (POST) the period of supplementation and training. Additional blood samples will be taken 48 hours after the first and last training sessions, for specific determination of blood muscle damage markers: CK and LDH.

NCT ID: NCT04275726 Recruiting - Clinical trials for Aortic Valve Stenosis

LANDMARK Trial: a Randomised Controlled Trial of Myval THV

LANDMARK
Start date: November 4, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study (LANDMARK) is to compare the safety and effectiveness of the Myval THV Series with Contemporary Valves (Sapien THV Series and Evolut THV Series) in patients with severe symptomatic native aortic valve stenosis. This study will be done in total 768 subjects (384:384, Myval THV Series vs. Contemporary Valves) The randomisation will be carried out with an allocation ratio of 1:1 between Myval THV Series vs. Contemporary Valves (Sapien THV Series and Evolut THV Series)

NCT ID: NCT04274439 Recruiting - Chronic Pain Clinical Trials

Effectiveness and Cost-Effectiveness of a Tele-Rehabilitation Program in the Treatment of Chronic Musculoskeletal Pain

Start date: March 3, 2020
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to develop and test the effectiveness and cost-effectiveness of an internet-based self-management program based on pain education and exercise for people with chronic musculoskeletal pain.

NCT ID: NCT04273945 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

UNISUS
Start date: June 30, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

NCT ID: NCT04273828 Recruiting - Back Pain Clinical Trials

Impact of Muscle Degeneration in Chronic Low Back Pain

Start date: April 6, 2020
Phase:
Study type: Observational

Surgical interventions for the removal of intervertebral disc fragments or to enlarge a narrow spine canal are commonly performed worldwide and are considered efficient. Concomitant low back pain is not uncommon among patients with lumbar nerve compression and neurological symptoms. When present, controversy persists in the literature regarding its ideal management. Although neurological symptoms improve after decompressive surgery, the presence of residual chronic low back pain may worsen satisfaction scores and cause functional disability. The hypothesis of the present study is that the presence of atrophy of the paraspinal and trunk muscles predicts chronic low back pain after lumbar neural decompression. If confirmed, this finding will aid in better planning of physical rehabilitation strategies for this group of patients, as well as a clearer prediction regarding surgical treatment outcomes for patients and health professionals.